The present disclosure is directed to compositions comprising as an active ingredient, a lower dose of 4-({(1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl] amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof for treating or preventing vasomotor symptoms in a subject, and methods which comprises administering the said compound or the pharmaceutically acceptable salt thereof at a lower dose, respectively.
